A Europe-wide review of intravenous iron products for iron deficiency and anaemia recommended strengthened measures to manage and minimise the risk of hypersensitivity reactions, which may be life-threatening or fatal.
An initial test dose was previously recommended for some products; there are however no data to show that this minimises risk, and it may give false reassurance (as hypersensitivity reactions have been reported in patients with a negative initial test dose). An initial test dose on first use of an IV iron product is therefore no longer recommended.
For further information, please see a related Drug Safety article from the MHRA at the link below.